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Abstract 
 
Background 
 
While Beta blockers (BB) and Angiotensin converting enzyme 
inhibitors/Angiotensin receptor blockers (ACEinh/ARB) are important components 
in advanced heart failure (HF) therapy, their use after left ventricular assist device 
(LVAD) implantation remains controversial. Concern has been raised about 
possible adverse effects of BB on right ventricular (RV) function while tolerance 
and efficacy/outcome data for ACEinh are lacking. This study aimed to 
characterize the use of medical therapy post-LVAD implantation and to evaluate its 
safety and efficacy. 
  
Methods 
Demographic, clinical and echocardiographic variables of patients implanted with a 
continuous-flow LVAD between 2012 and 2015 at a single center were 
retrospectively reviewed. Mortality and HF hospitalizations were followed from 6-
18 months’ post-implant.  
Results 
Of a total of 98 patients, the mean age was 57 years, 81% were men and 61% had 
ischemic disease. While the use of diuretics decreased considerably post LVAD, 
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over 50% continued to require diuretics. At 6th month post-implantation, 73% of 
patients were on BB, and these patients had significantly lower proBNP at 6 and 
12 months follow up. Despite significant prevalence of RV dysfunction in the cohort 
(>75% at 6 months), there was no significant difference in HF hospitalizations 
based on BB use (14% vs 15%) and instead a trend towards less deaths in those 
on BB (6% vs 15%). ACEinh/ARB use was likewise common at 6 month (61%) 
and these patients had lower pro B-type natriuretic peptide (proBNP) at 6 and 12 
months, lower right atrial (RA) pressures (9 vs 12 mmHg, p=0.03), and a 
significantly lower mortality—a finding which remained significant on multivariate 
analysis.  
Conclusion 
The use of ACEinh/ARB appeared to be associated with subsequent improved 
survival, lower proBNP and RA pressures. The use of BB post-LVAD appears safe 
and was associated with a lower proBNP, even in a patient population with a 
significant prevalence of RV dysfunction.  
Keywords: Left ventricular assist device, advanced heart failure management, 
heart failure hospitalization 
Abbreviations: BB= Beta blockers, ACEinh/ARB= Angiotensin converting enzyme 
inhibitors/Angiotensin receptor blockers, RV= right ventricle, RA= right atrium, 
LVAD= left ventricular assist device, CHF= congestive heart failure, proBNP= pro-
B-type natriuretic peptide, GDMT= goal directed medical therapy, NYHA= New 
York Heart Association, INTERMACS= Interagency Registry for Mechanically 
Assisted Circulatory Support, MAP= mean arterial pressure, LDH= lactate 
dehydrogenase, LVEDD= left ventricular end diastolic diameter, AI= aortic 
insufficiency, MR= mitral regurgitation, TR= tricuspid regurgitation 
 
Background  
While reverse remodeling and optimal heart failure medical therapy is recognized 
as an important component in the management of patients with advanced heart 
failure (1), this goal directed medical therapy (GDMT) is often not given to patients 
following Left Ventricular Assist Device (LVAD) implantation and its use post-LVAD 
implantation remains controversial (2). Recipients of mechanical support have 
advanced heart failure and are likely to have a similar neurohormonal milieu to 
other advanced heart failure patients (3,4). Furthermore the right side of the heart 
is unsupported and the addition of the device may lead to worsening of right 
ventricular (RV) dysfunction following LVAD implantation due to septal shift and 
increased flow to the RV. Hence these patients may continue to suffer from 
adverse cardiovascular comorbidities such as ongoing fluid retention leading to 
heart failure hospitalizations. Patients post implant may therefore potentially derive 
benefit from angiotensin system and beta blockade which might improve their 
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quality of life and reduce hospitalizations and adverse events. Such therapy also 
results in better blood pressure control hence decreasing the incidence of stroke 
(5) on LVAD support. Furthermore, neurohormonal antagonists, beta blockers, and 
aldosterone antagonists all significantly facilitate ventricular reverse remodeling 
and reduce fibrosis leading to myocardial recovery and subsequent explantation in 
some cases (6,7). Despite these potential benefits, concerns have been raised 
about the safety of GDMT, due to possible deleterious effects of beta-blockers on 
right ventricular (RV) function after LVAD implantation as well concerns regarding 
their tolerance (8). Particularly given the high morbidity related to both early and 
late RV dysfunction post LVAD implantation, optimizing medical therapy has 
becomes a controversial dilemma. Whether beta blocker therapy is beneficial or 
detrimental for RV dysfunction after LVAD implantation has not been determined. 
Beneficial effects of beta blockers in VAD patients have preliminarily been 
suggested in a recent abstract (9), however published data on the potential 
benefits of beta blockers and other heart failure therapy remains scarce. With the 
rising cohort of LVAD patients each year (10), there is an increasing need for data 
to understand the post-implantation optimum medical therapy that will result in the 
best outcomes.  We aimed to determine the effect of heart failure medical therapy 
on the outcomes and adverse events in patients implanted with an LVAD at a 
tertiary heart failure center.  
 
Methods  
Study population: 
We performed a retrospective review of consecutive patients implanted with a 
continuous flow LVAD-HeartMate II(Abbott, Abbott Park, IL) or Heart-Ware 
(Medtronic, Minneapolis, MN), between January 2012 and December 2015 at a 
tertiary care facility. Appropriate Institutional Review Board exemption was 
obtained. Exclusion criteria included patients with their first LVAD placed prior to 
2012 with re-implantation in the study period, an LVAD placed elsewhere, or 
death/transplant within 6 months of implant (as these patients would not have data 
available for collection at 6 months post implant). Key patient demographics and 
echocardiographic variables were collected prior to-implant and 6 months after 
implantation and key laboratory findings were collected pre implant, 6 months, and 
12 months post LVAD-implant. Medication use and doses including beta-blocker in 
metoprolol equivalent, angiotensin converting enzyme inhibitor (ACEinh) or 
angiotensin receptor blockers (ARBs) in lisinopril equivalent, loop diuretics in 
bumetanide equivalent, calcium channel blockers in amlodipine equivalent, 
spironolactone, metolazone, hydralazine and nitrate use before implant, and at 6 
and 12 months post-implant were collected. Heart failure and other medication use 
was at the discretion of the advanced heart failure team based on individual 
practice pattern and patient tolerance, and were often initiated as early as implant 
admission or on early outpatient follow-up. Data on mortality and heart failure 
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hospitalizations were collected from 6 to18 months post-implant (the 12 month 
study window). Loss of patients to follow-up or missing follow-up data was 
expected to be rare, as our facility is the only LVAD center in the area and we are 
notified when our patients present elsewhere and routinely transfer LVAD patients 
to our facility. 
Echocardiographic (echo) data at 6 months post-implant was collected 
retrospectively from reports.  Echocardiograms were routinely performed at this 
time frame as per our program protocols, and only echocardiograms performed 
during outpatient follow up (in compensated state) were included. Assessment of 
chamber size or function was based on the American Society of Echo guidelines 
(11). Right atrial pressure was derived through echocardiographic assessment. 
Not all echo variables were available on all patients due to poor image quality or 
uninterpretable data and these data points were excluded from the study. Variable 
that were not available were left as missing from data analysis. Congestive heart 
failure (CHF) hospitalization was defined as admission secondary to fluid overload 
with signs and symptoms requiring hospital-based medical treatment with 
diuretics, occurring between 6-18 months after implantation. Mean arterial 
pressure was reported based on program protocols using the mean pressure 
obtained from an automated non-invasive measurement or a Doppler.  
Statistical analysis: 
Forward and backward conditional multivariate logistic regression analysis was 
performed using demographic, medication and echocardiography data to identify 
predictors of hospitalization and mortality. The variables used for the above 
analysis included age, gender, diabetes, individual medication use, mean arterial 
pressures, serum creatinine. Significance was defined at p-value ≤0.05. 
 
IBM SPSS (version 19.0, SPSS Corp, Chicago, IL, USA) was used for statistical 
analysis. Qualitative data is presented as frequencies and quantitative data as 
mean ± standard deviation. Categorical variables were compared by using Chi-
square test, and continuous variables were compared using Student’s t-test. 
Paired t-test was used for numerical variables and McNemar test was used for 
nominal variables for before and after implantation comparison. Prevalence and 
percentages in the table represent patients with available and interpretable data 
for each variable. Microsoft Excel 2013 was used for building charts and figures. 
Results  
In total, 138 patients had an LVAD placed and were discharged between January 
2012 and December 2015, of which 9 patients underwent LVAD placement twice 
in the study period and 31 patients were also excluded based on the exclusion 
criteria (Figure 1). Thus, 98 patients (58 HeartMate II, 40 HeartWare) were 
identified for inclusion into the study.  
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Figure 1. Selection criteria for the study 
Paired comparison of individual patients (before and after implant) is summarized 
in Table 1.  
Table 1. Paired-statistic comparison of patients before and 6 months after 
LVAD implantation 
 Pre-implant 6 months P-value 
NYHA class 3 & 4 patients (n) 98 (100%) 3 (3%) 0.01 
Creatinine (mg/dL) 1.36 ± 0.56 1.36 ± 0.75 0.79 
Albumin(g/dL) 3.37 ± 0.49 3.68 ± 0.51 0.01 
Bilirubin (mg/dL) 1.56 ± 1.22 1.19 ± 2.90 0.32 
LDH(U/L) 224 ± 130.36 225.9 ± 72.40 0.69 
ProBNP (pg/mL) 4670.86 ± 3728.55 2538.06 ± 4052.37 0.01 
Greater than moderate AI (n) 23 (31.5%) 11 (15%) 0.02 
Greater than moderate MR (n) 37 (40%) 20 (27%) 0.15 
Greater than moderate TR (n) 20 (22%) 9 (12%) 0.07 
RA pressure (mm Hg) 12.82 +- 4.97 11.00 +- 4.47 0.04 
Greater than moderate RV 
enlargement(n) 
28 (40.6%) 37 (53.6%) 0.16 
Greater than moderate RV 
dysfunction (n) 
47 (64.4%) 55 (75.3%) 0.20 
LVEDD (cm) 7.08 +- 1.25 6.30 +- 1.37 0.01 
 
Mean patient age was 57 ± 14 years and 79 patients (81%) were male. The cause 
of heart failure was ischemic in 41 patients (61%) and 69 patients (70%) were 
implanted as destination therapy.  On LVAD support, the mean arterial pressure 
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was 89 ± 13 mmHg at 6 months and 85 ± 12 mmHg at 12 months. At 6 and 12 
months, only 3% and 4% of patients respectively were New York Heart 
Association Class III and IV. There was a trend towards more RV dilation and 
dysfunction on the 6 month echocardiogram compared to baseline, although this 
did not meet statistical significance. A total of 14 (14%) patients were hospitalized 
with CHF exacerbation and 8 patients (8%) died during the 6-18 months of follow 
up. 
The frequency of use of diuretics and heart failure medications as well as the 
equivalent doses used pre implant, and at 6 and 12 months post-LVAD is shown in 
Table 2.  
Table 2: Use of GDMT, diuretics, and calcium-channel blockers (CCB) prior 
to and post LVAD implant. 
Medications Pre-implant 6 months 12 months 
Metolazone (n) 22 (23.2%) 9 (9.2%) 11 (12.9%) 
Spironolactone (n) 62 (63.9%) 53 (54.1%) 40 (47.6%) 
Beta blocker (n) 76 (77.6%) 72 (73.5%) 71 (84.5%) 
ACEinh/ARB (n) 53 (54.1%) 59 (60.8%) 55 (66.3%) 
Loop Diuretic (n) 88 (90.7%) 56 (58.1%) 47 (56%) 
Nitrates (n) 11 (11.3%) 6 (6.1%) 5 (6%) 
Hydralazine (n) 10 (10.3%) 35 (36.1%) 35 (41.7%) 
CCB (n) 1 (1%) 14 (14.3%) 13 (15.7%) 
Aspirin (n) 77 (78.6%) 91 (92.9%) 75 (89.3%) 
Bumex equivalent (mg) 3.06 +- 2.04 1.26 +- 1.77 1.41 +- 2.01 
Metoprolol equivalent (mg) 64.05 +- 66.93 81.66 +- 104.53 103.07 +- 122.30 
Lisinopril equivalent (mg) 6.53 +- 11.76 16.40 +- 37.27 14.88 +- 38.20 
 
Figure 2 shows the percentage of patients on various heart failure and anti-
hypertensive medications before and after implantation. Figure 3 depicts the 
number of medications prescribed to patients during the same time period (from 0 
to ≥4 medications).  While the use of loop diuretics decreased from pre-implant to 
post-implant, more than 50% of patients continued to require loop diuretics at 6 
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and 12 months post implant.  Thiazide diuretic remained similar pre and post 
implant.  The use of beta-blockers, ACEinh/ARBs, and spironolactone, 
Hydralazine and calcium channel blockers was relatively high post-LVAD at our 
center. Figure 4 describes the trend of beta-blocker, ACEinh/ARB and loop diuretic 
dosage prescription before and after implantation. The rate of pre-LVAD medical 
therapy use was similar compared to prior advanced heart failure cohorts. 
 
Figure 2: Use of GDMT, diuretics, and CCB prior to and post LVAD implant 
 
Figure 3: Number of GDMT meds and CCB prescribed prior to and post 
LVAD implantation 
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Figure 4: Trend of medication doses pre and post-implant 
Table 3 depicts the demographic, laboratory, echocardiographic and outcome data 
of patients on and off beta blockers, ACEinh/ARB, and spironolactone. Patients on 
BBs were younger and more likely to be men and patients on ACEinh/ARB were 
younger and had better renal function, though the key laboratory and echo 
characteristics were otherwise similar between those on and off these therapies.  
Blood pressures at 6 and 12 months were not significantly different among patients 
on versus off medical therapy (data not shown), as therapy was often titrated to 
achieve a desired blood pressure.  
At 6 months post-implantation, 72 patients (73%) (44 HeartMate II, 28 Heart-Ware) 
were on beta-blockers with a daily metoprolol equivalent dose of 82 mg (± 105) 
mg. Beta-blocker use was similarly distributed among patients irrespective of the 
severity of the underlying RV dilation or dysfunction.  Beta blockers at 6 months 
were used in 74%, 68%, and 78% of patients with normal/mild, moderate, or 
greater than moderate degree of RV dysfunction respectively based on the 6 
month echo. Likewise, beta blockers were used in 82%, 64% and 71% of patients 
with normal/mild, moderate, or greater than moderate degree of RV dilation 
respectively based on the 6 month echo. Despite a significant prevalence of RV 
dilation and dysfunction in the cohort, there was no significant difference in heart 
failure hospitalizations with BB use (14% vs 15%) and instead a trend towards less 
deaths in those on BB (6% vs 15%). Patients on beta-blockers also had 
significantly lower proBNP at 6 months (1915 ± 2860 vs 4217 ± 5983 pg/mL, p= 
0.01) and a trend towards lower BNP at 12 months (2260 ± 4538 vs 5188 ± 10590 
pg/mL, p= 0.08).  
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Table 3 A: Comparison of variables on and off GDMT medications, all 
variables correlate with 6 month data unless specified 
 
 Beta-Blocker therapy ACEinh/ARB therapy 
On therapy Off therapy P-
value 
On 
therapy 
Off 
therapy 
P-
value 
Age (years) 55 ±14 63 ± 11 0.02 54 ±14 62 ± 12 0.04 
Males (n) 62 (86%) 17 (65%) 0.02 47 (80%) 32 (84%) 0.57 
Ischemic 
cardiomyopathy (n) 
63% 62% 0.93 63% 63% 0.96 
MAP (mm Hg) 87.69 ± 
13.8 
90.81 ± 11.8 0.31 88.31 ± 
13.4 
89.08 ± 
13.4 
0.78 
Creatinine (mg/dL) 1.4 ± 0.7 1.4 ± 0.8 0.78 1.1 ± 0.3 1.7 ± 1.1 0.01 
Bilirubin (mg/dL) 0.9 ± 0.4 1.1 ± 1.2 0.25 1.2 ± 3.7 1.1 ± 1.0 0.91 
LDH (U/L) 225 ± 78 229 ± 53 0.79 221 ± 78 233 ± 63 0.43 
Albumin (g/dL) 3.7 ± 0.5 3.5 ± 0.6 0.08 3.8 ± 0.4 3.4 ± 0.6 0.01 
proBNP (at 6 months) 
pg/ml 
1915 ± 
2860 
4217 ± 5983 0.01 1186 ± 
1106 
4715 ± 
5784 
0.01 
proBNP (at 12 
months) pg/ml 
2260 ± 
4538 
5188 ± 
10590 
0.08 1356 ± 
1280 
5590 ± 
10015 
0.01 
LVEDD (cm.) 6.5 ±1.4 5.7 ± 1.2 0.03 6.3 ±1.5 6.3 ± 1.0 0.90 
RA pressure (mm Hg) 10 ± 4 11 ± 4 0.67 9 ± 3 12 ± 5 0.03 
Greater than 
moderate AI (n) 
8 (14%) 3 (16%) 0.85 4 (6%) 7 (18%) 0.06 
Greater than 
moderate MR (n) 
14 (26%) 6 (32%) 0.63 9 (21%) 10 (35%) 0.20 
Greater than 
moderate TR (n) 
6 (11%) 3 (15%) 0.64 5 (11%) 3 (11%) 0.97 
Greater than 
moderate RV dilation 
(n) 
10 (71.4%) 4 (28.6%) 0.28 8 (17%) 6 (22%) 0.71 
Greater than 
moderate RV 
dysfunction (n) 
28 (77.8%) 8 (22.2%) 0.75 22 (49%) 14 (50%) 0.92 
CHF hospitalization 
(n) 
10 (14%) 4 (15%) 0.85 8 (14%) 6 (16%) 0.76 
Death (n) 4 (6%) 4 (15%) 0.12 1 (2%) 7 (18%) 0.01 
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Table 3 B: Comparison of variables on and off other spironolactone, all 
variables correlate with 6 month data unless specified 
 On spironolactone 
(n=53) 
Off spironolactone 
(n=45) 
P-value 
Age (years) 53 ±14 63 ± 12 0.01 
Males (n) 41 (77%) 38 (84%) 0.37 
Ischemic cardiomyopathy (n) 49% 78% 0.03 
MAP (mm Hg) 87.13 ± 13.6 90.13 ± 13.0 0.27 
Creatinine (mg/dL) 1.1 ± 0.4 1.5 ± 1.0 0.01 
Bilirubin (mg/dL) 1.4 ± 3.8 1.0 ± 1.0 0.49 
LDH (U/L) 216 ± 76 239 ± 66 0.12 
Albumin (g/dL) 3.8 ± 0.5 3.6 ± 0.5 0.09 
proBNP (at 6 months) pg/ml 1813 ± 3058 3431 ± 4907 0.05 
proBNP (at 12 months) pg/ml 1419 ± 1276 4635 ± 9116 0.02 
LVEDD (cm.) 6.3 ±1.6 6.1 ± 1.1 0.60 
RA pressure (mm Hg) 10 ± 4 11 ± 5 0.20 
Greater than moderate AI (n) 4 (10%) 7 (21%) 0.14 
Greater than moderate MR (n) 13 (33%) 7 (21%) 0.28 
Greater than moderate TR (n) 5 (12%) 4 (13%) 0.93 
Greater than moderate RV 
dilation (n) 
7 (18%) 7 (22%) 0.71 
Greater than moderate RV 
dysfunction (n) 
19 (45%) 17 (53%) 0.50 
CHF hospitalization (n) 7 (13%) 7 (16%) 0.74 
Death (n) 3 (6%) 5 (11%) 0.32 
  
At 6 months post implantation, 59 patients (60%) (32 HeartMate II, 27 Heart-Ware) 
were on an ACE inhibitor or ARB, with an average lisinopril equivalent dose of 16 
± 37mg/day.Although  patients on an ACE inhibitor had worse NYHA Class prior to 
LVAD implantation, they had significantly lower proBNPs at 6 and 12 months 
following LVAD implant as well as a lower RA pressure compared to those not on 
an ACE inhibitor. Over the 6-18 month follow-up period, the mortality rate was 1/60 
(2%) among patients on ACEinh/ARB and 7/38 (18%) among patients not on 
ACEinh/ARB (p= 0.01).  The beneficial effect on survival remained significant in 
multivariate analyses accounting for age, gender, renal function, and concomitant 
medication use (Odds ratio: 0.07, Confidence Interval 0.009-0.649, p = 0.018). 
Key variables for patients with and without a CHF hospitalization between 6-18 
months after LVAD implantation are shown in Table 4. Patient who experienced a 
hospitalization were more likely to be on diuretic at 6 months (p= 0.021) and were 
on a higherbumetanideequivalent dose than the non-hospitalized group (2.24 ± 2.2 
vs 1.01±1.5mg, p= 0.002). In multivariate analysis including age, gender, renal 
function, and medication use, diuretic use at 6 months remained a predictor of 
subsequent CHF hospitalization (Odds ratio: 5.7, Confidence Interval 1.2-27.2, p = 
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0.029).  When echo parameters were included in the multivariate model, only RA 
pressure of  ≥ to 12.5 mmHg at 6 months remained predictive of subsequent CHF 
hospitalizations (Odds ratio: 1.228, 95% Confidence Interval 1.040-1.451, p = 
0.01). 
Table 4: Six months patient characteristics and association with subsequent 
heart failure hospitalization over the following 12 months 
At 6 months CHF hospitalization P value 
Yes No 
On metolazone(n) 4 (23%) 5 (6.1%) 0.02 
On diuretic (n) 14 (82.3%) 42 (51.8%) 0.02 
NYHA class 3 or 4 (n) 2 (11.7%) 1 (1.2%) 0.02 
MAP (mm Hg) 86.33 ± 6.55 87.00 ± 13.37 0.865 
Bumex equivalent (mg) 2.44 ± 2.23 1.01± 1.56 0.01 
RA pressure (mm Hg) 13.57 ± 4.75 9.43 ± 3.78 0.01 
Greater than moderate RV dilation (n) 8 (62%) 31 (50%) 0.44 
Greater than moderate RV dysfunction (n) 10 (77%) 49 (74%) 0.83 
Greater than moderate AI (n) 3 (25%) 8 (13%) 0.25 
Greater than moderate MR (n) 3 (27%) 17 (27%) 0.99 
Greater than moderate TR (n) 0 (0%) 9 (14%) 0.15 
LVEDD (cm.) 6.40 ± 0.90 6.25 ± 1.39 0.72 
Aortic valve opening (n) 4 (36%) 56 (47%) 0.50 
 
There were 7 admissions for implanted defibrillator discharge but BB use was not 
associated with any significant difference (p= 0.09 at 6 months and p= 0.23 at 12 
months).Death between 6-18 months in our cohort occurred in 8 patients. Causes 
included progressive renal failure/multi-organ failure (4 patients), withdrawal of 
care/hospice (3 patients), PEA and presumed bacteremia (1 patient). 
Discussion 
The past decade has seen LVAD implantation become mainstream in the 
management of advanced heart failure through significant improvement in the 
reliability, safety and longevity of the pumps. With increasing demand and 
unchanged availability of transplant-eligible hearts, LVAD implantation can be 
expected to increase with time. In the 9 years of Interagency Registry for 
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Mechanically Assisted Circulatory Support (INTERMACS) Registry, more than 
15,000 patients have been implanted with an LVAD in 158 participating 
institutions(10). However, there is no clear understanding and a surprising lack of 
evidence about the role of heart failure therapy post LVAD implantation(2). Among 
our cohort, the use of heart failure therapy post LVAD implantation appeared safe 
and beneficial, which has important clinical implications for the medical 
management of this growing group of patients.  
Angiotensin inhibitors post LVAD 
Here, we show, for the first time, that patients receiving an ACE inhibitor (despite 
being in a worse NYHA Class prior to LVAD implantation in our series) had 
significantly lower proBNPs at 6 monthsand 12 monthsfollowing LVAD implant and 
better survival after LVAD implantation both in univariate and multivariate 
analyses. Patients on an ACE inhibitor or ARB also had a subsequent lower RA 
pressure compared to those not on an ACEinh/ARB suggesting a potential 
beneficial effect on RV function. 
There are several potential mechanisms to explain the beneficial clinical effects of 
angiotensin system blockade post implantation. Use of ACEinh/ARB have been 
reported to reverse myocardial remodeling(12) and arteriovenous malformation 
related gastrointestinal bleeding(13) among post-LVAD patients, however efficacy 
and mortality data have been lacking so far. In a retrospective study of 131 
patients(13), use of ACEinh/ARB was an independent factor in reducing the risk of 
significant gastrointestinal bleeding, including arteriovenous malformation 
associated bleeding. In a study of myocardial biopsy samples pre and post-LVAD 
implantation, Klotz et al reported low myocardial collagen content and stiffness 
post-LVAD implantation in patients prescribed angiotensin system blockers, 
possibly suggesting reverse remodeling in these patients(12). The findings of the 
present study suggest that these or other mechanisms may have clinical utility 
through improved outcomes including survival. These finding will need to be 
validated however in larger patient cohorts, such as INTERMACS. 
Beta blockade post LVAD 
 
Our fairly well characterized cohort also suggested that beta blockers are 
potentially beneficial post LVAD implantation. Despite a population with a 
significant prevalence of RV dilation and dysfunction, patients on beta-blockers 
had a significantly lower proBNP 6 months after LVAD implantation and a trend 
towards a lower BNP at 12 months. Beta blockers furthermore appear safe as 
there was no significant difference in the frequency of heart failure hospitalization 
with beta blocker use and a trend towards lower mortality in those on beta 
blockers. 
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Beta-blockers are widely used for left ventricular failure but their role in right 
ventricular failure  (and therefore their role post LVAD implantation) remains 
unestablished with even a suggestion of a negative effect(8) Although the possible 
negative effect is a widely held belief, the evidence for it is extremely sparse. 
Pulmonary arterial hypertension is considered a relative contraindication for beta-
blocker use due to concerns of a possible negative effect on hemodynamics and 
exercise capacity. However this is only based on a small study of 10 patients with 
porto-pulmonary hypertension in which withdrawal of propranolol was associated 
with improved exercise tolerance and on one case report (14-16). Furthermore 
more recent literature in patients with pulmonary hypertension and congenital 
heart disease suggests otherwise with improvements in RV re-modelling(17) and 
RV end-diastolic volumes(18) with beta blocker therapy, and such therapy having 
no deleterious effect on exercise capacity or mortality (18,19). Beta blockers have 
been shown to improve RV function and prevent myocardial re-modelling in animal 
models of pulmonary hypertension(17,20) as well as to reverse the characteristic 
‘molecular signature’ of RV failure(21). In humans a small single arm study of beta 
blockers in patients post correction of transposition of the great arteries showed 
improvements in symptoms, quality of life and RV ejection fraction(22). 
Furthermore more recently, a prospective cohort study of 94 PAH patients found 
no increase in adverse clinical or hemodynamic consequences in the 285 patients 
on beta blockers for other cardiac co-morbidities(19). However we continue to lack 
large prospective trials to prove the role of beta-blockers in RV failure(23). Our 
data certainly suggests no increase in adverse events with beta blocker use on 
clinical right ventricular function with potential beneficial clinical effects. 
 
Another potential mechanism of beta blocker benefit is through arrhythmia 
prevention. The risk of ventricular arrhythmia is significant after LVAD placement 
and arrhythmia can worsen RV function. Early beta-blockade is certainly 
suggested in patients with pre-or post-LVAD history of arrhythmias(24), and one 
mechanism of the benefit can be through RV preservation(25). 
Myocardial Recovery 
 
Mechanical unloading with an LVAD can lead to sufficient reverse remodeling and 
improvement in myocardial function to allow explantation of the device and leave 
the patient with a good quality of life. However the rate at which this occurs has 
been highly variable and it is likely that neuro-hormonal antagonists, beta blockers, 
and aldosterone antagonists all significantly facilitate ventricular reverse 
remodeling and reduce fibrosis leading to myocardial recovery and subsequent 
explantation in a higher proportion of cases after LVAD support. LVAD patients 
continue to have pathological re-modelling and increase in myocardial 
stiffness(26). Two  prospective studies(6,7) have suggested that aggressive up-
titration of reverse remodeling heart failure therapy including high dose ACEinh 
and beta-blockers is associated with improvement in severe heart failure from non-
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ischemic cardiomyopathy and successful device explantation in patients through 
reversal of the pathological re-modelling.  The demonstration that angiotensin 
system inhibitors and beta blockers appear safe in LVAD recipients may allow for 
their greater use and therefore greater possibility of eventual explantation. Prior to 
LVAD implantation, patients usually become intolerant to these therapies due to 
hypotension and renal failure (from the low cardiac output), but the improved flow, 
better blood pressure and improved renal function provided by the LVAD may 
allow up-titration of these drugs to very high doses thus making the LVAD a 
platform for myocardial recovery.  
 
The trend towards a greater degree of RV dilation and dysfunction on the post-
VAD echocardiograms at 6 months is of unclear significance. Possible 
explanations include an increase in venous return due to improved left sided 
cardiac output and potential effects of LV suction on the ventricular septum. 
 
Clinical Implications 
 
Similar to our findings, a recent study from the INTERMACS data(2) noted an 
increase in prescription of ACEinh, ARBs and beta-blockers 3 months and 6 
months post-implantation. While the use of loop diuretics declined after 
implantation in the INTERMACS cohort, the number still remained considerably 
high (>55% patients). The study also reported highest beta-blocker use in younger 
patients which is similar to our present study. These findings are similar to the 
practice pattern in our hospital, making our results potentially applicable to larger 
populations.  Not all patients in the INTERMACS cohort were prescribed GDMT 
post-implant and this could be indicative of individual patient intolerance to these 
medications but also likely signify the uncertainty and lack of guidelines. Currently, 
the International Society for Heart and Lung Transplantation (ISHLT) recommends 
utilization of heart failure medications (ACEinh, ARBs and beta-blockers) for blood 
pressure or tachyarrhythmia management(27) but no recommendation has been 
made for their continued utilization in LVAD patients for management of heart 
failure per se. ACE/ARB and beta blockers will also lower blood pressure in LVAD 
patients which will have a secondary beneficial effect by lowering the stroke 
risk(5). Our current results highlight a potential beneficial role for these therapies 
above and beyond blood pressure and arrhythmia prevention by demonstrating 
both safety and potential efficacy in our cohort.  
We also found that risk of heart failure hospitalization during follow up was 
associated with diuretic use and with higher RA pressure(table 4), suggesting a 
possible association with “late RV failure”. These findings may have important 
implications for optimizing medical therapy post LVAD implantation and for 
identifying patients at highest risks for adverse events.  
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Limitations 
The limitations of the study include the retrospective design and single facility. The 
study was underpowered to perform significant subset analysis or present a 
prediction model. This study aimed at understanding the outpatient practice 
pattern in LVAD implanted patients and evaluating the safety of continued 
prescription of beta-blockers and other heart failure medical therapies. Also the 
difference in prescription of medications (ACEinh and diuretics) in subgroup 
analysis for predictors may be confounded by individual intolerance and not clearly 
indicate efficacy. Medication use at the 6 month time-point only was used for 
statistical analysis and the use or duration of heart failure therapy prior to or after 
the 6 month time frame may have varied among patients. The position of the 
ventricular septum was not addressed on all studies.  
 
Conclusion 
In conclusion this study presents a well characterized cohort of advanced heart 
failure patients post LVAD implantation, with several key findings. We demonstrate 
that the use of angiotensin system inhibitors appeared to be associated with lower 
pro-BNP, RA pressure, and most importantly improved survival. We also 
demonstrate that beta blocker therapy appears safe, including in patients with 
significant right ventricular dysfunction, and may be beneficial in patients post 
LVAD implantation by being associated with a lower pro-BNP. The use of beta-
blocker and angiotensin system inhibitors in LVAD patients need further 
investigation, however, this study provides evidence to support their use post 
LVAD implantation. In general, these drugs may not be used as prolifically as they 
should be, most likely due to the lack of evidence in this patient population. The 
current study highlights that the risks of heart failure therapies may be over-
exaggerated while the benefits may be underappreciated. 
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